GATC's Novel AI-Based End-to-End Drug Development Platform Identified Novel Drug Candidates for Opioid Use Disorder in Months Instead of Years

GATC’s Novel AI-Based End-to-End Drug Development Platform Identified Novel Drug Candidates for Opioid Use Disorder in Months Instead of Years

GATC Health Enters Clinical Development of Breakthrough Compounds for the Treatment of Fentanyl Addiction and Opioid Use Disorders The drug’s mechanism is potentially the first to rewire and restore the brain, addressing a root cause of opioid addiction and may have application for treating other neurological diseases IRVINE, Calif., October 6, 2022 /PRNewswire/ — GATC …

GATC’s Novel AI-Based End-to-End Drug Development Platform Identified Novel Drug Candidates for Opioid Use Disorder in Months Instead of Years Read More »